Cargando…

Cell-based therapies in kidney disease

Cell-based therapy is an emerging field but one that has shown early promise for the treatment of human kidney diseases. The most widely used cell is the mesenchymal stem cell (MSC) given its ability to be harvested from bone marrow, expanded in culture, and used in allogeneic protocols. The benefic...

Descripción completa

Detalles Bibliográficos
Autor principal: Rosenberg, Mark E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089669/
https://www.ncbi.nlm.nih.gov/pubmed/25019020
http://dx.doi.org/10.1038/kisup.2013.78
_version_ 1782325151451316224
author Rosenberg, Mark E
author_facet Rosenberg, Mark E
author_sort Rosenberg, Mark E
collection PubMed
description Cell-based therapy is an emerging field but one that has shown early promise for the treatment of human kidney diseases. The most widely used cell is the mesenchymal stem cell (MSC) given its ability to be harvested from bone marrow, expanded in culture, and used in allogeneic protocols. The beneficial effects of MSCs occur through differentiation-independent pathways that include increased cell survival and proliferation, decreased inflammation, and suppression of immune function. Acute kidney injury and kidney transplantation are the two conditions most frequently treated with MSC infusion. Although initial studies are promising, the long-term efficacy and safety of MSC infusion awaits further study.
format Online
Article
Text
id pubmed-4089669
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40896692014-07-11 Cell-based therapies in kidney disease Rosenberg, Mark E Kidney Int Suppl (2011) Meeting Report Cell-based therapy is an emerging field but one that has shown early promise for the treatment of human kidney diseases. The most widely used cell is the mesenchymal stem cell (MSC) given its ability to be harvested from bone marrow, expanded in culture, and used in allogeneic protocols. The beneficial effects of MSCs occur through differentiation-independent pathways that include increased cell survival and proliferation, decreased inflammation, and suppression of immune function. Acute kidney injury and kidney transplantation are the two conditions most frequently treated with MSC infusion. Although initial studies are promising, the long-term efficacy and safety of MSC infusion awaits further study. Nature Publishing Group 2013-12 2013-11-27 /pmc/articles/PMC4089669/ /pubmed/25019020 http://dx.doi.org/10.1038/kisup.2013.78 Text en Copyright © 2013 International Society of Nephrology
spellingShingle Meeting Report
Rosenberg, Mark E
Cell-based therapies in kidney disease
title Cell-based therapies in kidney disease
title_full Cell-based therapies in kidney disease
title_fullStr Cell-based therapies in kidney disease
title_full_unstemmed Cell-based therapies in kidney disease
title_short Cell-based therapies in kidney disease
title_sort cell-based therapies in kidney disease
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4089669/
https://www.ncbi.nlm.nih.gov/pubmed/25019020
http://dx.doi.org/10.1038/kisup.2013.78
work_keys_str_mv AT rosenbergmarke cellbasedtherapiesinkidneydisease